![]() Under terms of the agreement Serotiny will receive an upfront payment and is eligible for certain future consideration, contingent upon the collaboration achieving pre-specified performance thresholds. Serotiny’s multi-domain engineering expertise has the potential to further optimize our Gene Writer protein libraries and we’re delighted to partner with the Serotiny team.” “Our R&D engine seeks to learn from billions of years of mobile genetic element evolution to generate novel Gene Writing systems with the ability to solve important challenges in genetic medicine. “Tessera’s mission is to cure disease by writing in the code of life and we’re committed to continuously innovating to improve and expand our Gene Writing platform,” said Geoffrey von Maltzahn, PhD, co-founder and CEO of Tessera. By partnering with Serotiny, Tessera will have the ability to identify, screen, and optimize a variety of proteins that can serve as the foundation of future Gene Writer therapies across a variety of disease states. Tessera’s Gene Writer candidates can allow the substitution, insertion, or deletion of DNA sequences, as well as the writing of entire genes into the genome, offering the potential for a new category of genetic medicines. “It provides Serotiny a unique opportunity to extend the validation of our platform and to continue to advance our efforts in discovering and developing proteins with novel function for the purpose of enhancing the therapeutic utility of next-generation genetic medicines.” “We’re extremely excited to be working with the Tessera team,” said Colin Farlow, J.D., Serotiny’s CEO. ![]() This collaboration will build on Tessera’s innovations in genome engineering technologies and apply Serotiny’s tMDP mining and design expertise to further optimize Tessera’s programmable Gene Writer proteins, capable of making diverse and directed alterations to the genome. Afeyan was previously employed as a Chairman by Evelo Biosciences, Inc., a Chairman by Rubius Therapeutics, Inc., a Co-Founder by Indigo Ag, Inc., a Lead Independent Director by Seres Therapeutics, Inc., a Chairman by Axcella Health, Inc., an Independent Director by Eleven Biotherapeutics, Inc., an Independent Director by BIND Therapeutics, Inc., a Chairman by Joule Unlimited Technologies, Inc., a Chairman by Theracrine, Inc., a Chairman by Codon Devices, Inc., a Lead Independent Director by Helicos Biosciences Corp., a Co-Founder by Epitome Biosystems, Inc., an Independent Non-Executive Director by BG Medicine, Inc., a Chief Business Officer & Senior Vice President by Applera Corp., a Co-Founder by Celera Genomics Group, a Chairman by ChemGenics Pharmaceuticals, Inc., a Chairman & Chief Executive Officer by PerSeptive Biosystems, Inc., a Chairman by Cygnal Therapeutics, Inc., a Chairman by Essentient, Inc., a Chairman-Global Agenda Council by Forum Mondial de L'Economie, a Co-Founder by Invaio Sciences, Inc., a Chairman by Laronde Inc., a Chairman by Repertoire Immune Medicines, Inc., and a Chairman-Global Agenda Council by The World Economic Forum USA, Inc.SAN FRANCISCO-( BUSINESS WIRE)-Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, and Tessera Therapeutics, a biotechnology company pioneering a new approach in genetic medicines known as Gene Writing technology, today announced a collaboration to engineer programmable Gene Writer proteins. ![]() He is on the Board of Directors at Cellarity Inc., Massachusetts Institute of Technology, IDEA Foundation, Ameriabank CJSC, Boston Symphony Orchestra, Inc., LS Dissolution, Inc., Armenia 2020, Armenian General Benevolent Union, Cobalt Biomedicine, Inc., Cogen Immune Medicine, Inc., Dilijan International School of Armenia, Epiva Biosciences, Inc., Inzen Therapeutics, Inc., Ring Therapeutics, Inc., Tessera Therapeutics, Inc. Afeyan is a Chairman at Omega Therapeutics, Inc., a Chairman at Moderna, Inc., a Founder & CEO at Flagship Pioneering, a Chairman at Alltrna, a Chairman at Generate Biomedicines, Inc., a Chairman at Profound Therapeutics, a Manager at Flagship Ventures Fund IV LP and a Manager at Flagship Ventures Fund IV-RX LP.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |